Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Ferry Brothers Partnership
WARNING LETTER
•Ferry Brothers Partnership•December 6, 2012

FDA WARNING_LETTER - Ferry Brothers Partnership - December 06, 2012

View on Dashboard

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Ferry Brothers Partnership
Record Details

The FDA conducted an inspection of Ferry Brothers Partnership's dairy operation from November 14 to December 6, 2012, identifying significant violations of the Federal Food, Drug, and Cosmetic Act. The primary violation involved the sale of an adulterated cow for slaughter on May 2, 2012. Tissue samples from this animal, analyzed by USDA/FSIS, revealed illegal drug residues of Ceftiofur, Sulfamethazine, and Flunixin in kidney, liver, and muscle tissues, exceeding established tolerances. This renders the food adulterated under section 402(a)(2)(C)(ii) of the Act. Furthermore, the inspection found that the firm holds animals under inadequate conditions, increasing the likelihood of medicated animals bearing harmful drug residues entering the food supply, constituting adulteration under section 402(a)(4). A specific deficiency noted was the failure to maintain drug treatment and drug inventory records, which contributes to these insanitary conditions and compliance issues. Ferry Brothers Partnership is required to take prompt corrective action to address these violations and establish procedures to prevent recurrence. A written response detailing these steps, including documentation, must be submitted to the FDA within fifteen working days. Failure to comply may lead to further regulatory actions, such as seizure or injunction, without additional notice.

Company
Ferry Brothers Partnership
Inspection Date
December 6, 2012
Product Type
Drugs
Office
New England District Office
Person
  • Amber G. Wardwell (Compliance Officer)
Open in Dashboard

ID · 815b1d25-7c78-4694-9f5a-29a7759ee668

Violation Codes3
21 U.S.C. 342(a)(2)(C)(ii)21 U.S.C. 360b21 U.S.C. 342(a)(4)

Full citation text and observation details available on the Dashboard.

KeyPedia
Regulatory Data Transformed
Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@globalkeysolutions.net
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.